Article Text

Download PDFPDF
Intestinal permeability in Behçet's syndrome
  1. I Freskoa,
  2. V Hamuryudana,
  3. M Demirb,
  4. N Hızlıc,
  5. H Saymanb,
  6. M Melikoğlua,
  7. R Tunça,
  8. S Yurdakula,
  9. H Yazıcıa
  1. aDepartment of Rheumatology, Cerrahpaşa Medical Faculty, Istanbul, Turkey, bDepartment of Nuclear Medicine, Cerrahpaşa Medical Faculty, cYeşilyurt State Hospital, Izmir, Turkey
  1. Dr Izzet Fresko, Yeşildirek, Tarakçi Cafer Sok, Hamarat Aykin Han 16, Istanbul, Turkey 34430freskoi{at}superonline.com

Abstract

OBJECTIVE To measure the intestinal permeability in patients with Behçet's syndrome (BS) and to compare the results with those obtained from healthy and diseased controls.

METHOD The study group comprised 34 patients with BS without known gastrointestinal disease. Ten patients with ankylosing spondylitis (AS), 6 with inflammatory bowel diseases (IBD), 17 with systemic lupus erythematosus (SLE), and 15 healthy subjects (HC) constituted the controls. All patients received 100 μCi (3.7 MBq) of chromium-51 EDTA (51Cr-EDTA) as a radioactive tracer after a 72 hour abstinence from all drugs. The percentage of the isotope excreted in a 24 hour urinary specimen was the measure of permeability.

RESULTS The percentage (SD) rate of excretion of 51Cr-EDTA was 4.6 (2.6) in BS, 6 (2.4) in AS, 5.2 (1.9) in IBD, 5.56 (1.78) in SLE, and 2.3 (1) in healthy controls. (Analysis of variance: f=6.4, p=0.0002. BSv HC, AS vHC, SLE v HC significant.)

CONCLUSION The intestinal permeability in BS was significantly more than that seen among the healthy controls. Similar results in all the diseased controls cast doubt on its specificity.

  • permeability
  • Behçet's disease
  • 51Cr-EDTA

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.